A recent meta-analysis concluded that metabolic syndrome is associated with a 2-fold increase in cardiovascular outcomes and a 1.5-fold increase in all-cause mortality [1] . While many studies investigate adult populations, the cohort investigated by Li et al. consisted of younger subjects aged 15-28 years recruited from the Beijing Child and Adolescent Metabolic Syndrome study and aimed to identify cardiovascular risk factors from childhood to adulthood [2] . Assessing the association of several GWAS-identified adiponectin-related genetic variants with left ventricular mass index (LVMI), used as a gauge of cardiovascular disease risk, these authors report (a) that CDH13 rs4783244 is positively correlated with adiponectin concentrations; (b) that this locus is also significantly associated with decreased LVMI independent of adiponectin concentrations and other conventional cardiovascular risk factors; and (c) that the cardio-protective effects at this locus are lost in subjects with short sleep duration.
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In a single study, Li et al. linked several important factors affecting cardiovascular risk in the presence of metabolic syndrome, namely genetics, metabolism, and sleep. They deserve special credit for their assessment of the role of sleep duration on cardio-protection gained from an adiponectin-related genetic variant in a young population diagnosed with the metabolic syndrome. Indeed, sleep duration is both predictive of the metabolic syndrome [3] and directly affects adiponectin [4] , a protein hormone involved in regulating glucose concentrations and fatty acid breakdown. Adiponectin, in turn, has been associated with both the metabolic syndrome [5] and cardiovascular health status gauged by LVMI [6] .
Specifically, a dose-response relationship exists between short sleep duration and the presence of metabolic syndrome, as shown by a metaanalysis of 75,657 participants in 18 studies [3] . Conversely, an increase in objective sleep duration is reportedly associated with a significantly increased serum adiponectin concentration, independent of the change in body fat during a 7-month weight loss intervention in overweight or obese women [4] . Low adiponectin concentrations at the outset and decreasing adiponectin concentrations over a 10-year follow-up are predictive of the metabolic syndrome [5] . Plasma adiponectin is also inversely correlated with LVMI and pulse wave velocity, the corresponding multiple regression model accounting for 73.3% of LVMI variability, results suggesting a direct influence of adiponectin on LVMI [6] .
Not mentioned in the paper by Li et al. and worth further investigation is the existence of a bidirectional relationship between adiponectin and the circadian system. Adiponectin expression is circadian periodic. It is mediated by the helix-loop-helix transcription factor sterol regulatory element binding protein (SREBP)-1c. In murine white adipose tissue and differentiated adipocytes, adiponectin expression is reportedly coordinated by the circadian system through the circadian expression of its transcription factor PPARγ and its co-activator PGC1α [7] . Conversely, circadian clock rhythmicity is modulated by adiponectin in a metabolic syndrome mouse model that expresses the human adiponectin transgene in the liver [8] . As compared to control mice, transgenic mice exhibit a blunted and phase-shifted circadian variation of locomotor activity. Transgenic mice also show phase-advanced circadian rhythms of the clock genes Arntl, Dbp, Cry2 and Per2 in both liver and skeletal muscles. Adiponectin may thus be a peripheral coordinator of the circadian clock in the brain and peripheral organs [8] .
Numerous studies have documented associations between circadian rhythmicity, sleep duration, and metabolism. Circadian disruption and disturbed sleep patterns can alter metabolism in a manner that predisposes to weight gain [9] . Alterations in the circadian clock machinery have also been linked to a host of disease conditions, including cardiovascular disease. The role of clock genes in relation to components of the metabolic syndrome (obesity and diabetes) is noteworthy since circadian clocks are tightly coupled to cellular metabolism as they share a number of nutrient-sensing pathways. Disease risk elevation and the presence of overt disease are also often associated with a weakened circadian system, with reduced circadian amplitude and a less tightly synchronized circadian system [10] .
A robust circadian system thus presents itself as a strategy for health maintenance and disease risk avoidance. Since environmental synchronizers such as the rest-activity schedule and meal timing are effective ways to strengthen the circadian system, it is not surprising that sleep and nutrition play such important roles in the presence of metabolic syndrome, as illustrated herein by the study of Li et al.
